Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

卷:1852

Review

Poulsen, Morten Moller¹ 

[1] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, MEA, DK-8000 Aarhus, Denmark

关键词: Resveratrol;    Inflammation;    Metabolism;    In vitro;    In vivo;    Clinical trial;   

DOI  :  10.1016/j.bbadis.2014.12.024

来源: Elsevier

【 摘 要 】

Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic comorbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. (C) 2015 Elsevier B.V. All rights reserved.

【 授权许可】

Free